Weight loss

#Atrogi #Obesity #Preclinical investigations #Stockholm University #Weight loss

Dual receptor beta-agonist promotes healthy weight loss

A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. Unlike existing anti-obesity therapies that compromise lean muscle mass, ATR-127 induces significant weight loss while preserving crucial lean body mass. ATR-127… Read More

#News

#Biomarkers #Machine learning #Phenomix Sciences #Weight loss

Test predicts obesity patients’ response to Ozempic

A new study has demonstrated the clinical utility of a machine-learning gene risk score biomarker to predict patient response to Ozempic (semaglutide) and reduce variability. The study ‘Performance of a Machine-Learning Gene Risk Score Biomarker on Predicting Response to Semaglutide’ was led by the Mayo Clinic… Read More

#News

#Diabetes #GlobalData #Market reporting #Weight loss

GLP-1 receptor agonists market to reach $125 billion by 2033

Glucagon-like peptide-1 (GLP-1) receptor agonist sales for the type 2 diabetes and obesity markets are forecast to reach over $125 billion in the seven major markets (7MM) by 2033, according to analysts GlobalData. GLP-1 receptor agonists like Ozempic (semaglutide) are a class of incretin mimetic medicines for the treatment of… Read More

#News #Trending News #Trends & Analysis

Patient using blood pressure monitor
#Cardiovascular disease #Novo Nordisk #Obesity #University College London #Weight loss

Ozempic could be a gamechanger for cardiovascular disease

Semaglutide (the active ingredient in Wegovy and Ozempic) can produce clinically meaningful weight loss and delivers significant cardiovascular benefits, according to two studies presented at the European Congress on Obesity (ECO). The studies are based on the Semaglutide and Cardiovascular Outcomes (SELECT) trial, the largest and… Read More

#News #Trending News

Stock market
#Diabetes #Eli Lilly #GlobalData #Market reporting #Novo Nordisk #Vertex #Weight loss

Lilly, Novo Nordisk and Vertex lead on market capitalisation growth

The top 20 global biopharmaceutical companies have reported 1.6% market capitalisation growth to $3.67 trillion in 2023, according to data analysts GlobalData. The top 20 global biopharmaceutical companies experienced varied year-on-year (YoY) market capitalisation shifts in 2023 amid the macroeconomic headwinds, steep patent cliffs and the commencement of US drug… Read More

#Business & Investment #News

#Eli Lilly #FDA #MHRA #Obesity #Regulatory #Weight loss

Tirzepatide approved for weight management in US and UK

The US Food and Drug Administration has approved Zepbound (tirzepatide) injection for chronic weight management alongside a reduced calorie diet and increased physical activity. It is approved in adults with obesity (body mass index of 30 kilograms per square meter (kg/m2) or greater) or overweight (body mass index of 27kg/m2… Read More

#News #Regulatory #Trending News